<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079438</url>
  </required_header>
  <id_info>
    <org_study_id>CARTOnG-2103</org_study_id>
    <nct_id>NCT05079438</nct_id>
  </id_info>
  <brief_title>Dendrobium Huoshanense Suppository in Rectal Cancer</brief_title>
  <official_title>A Multicenter Randomized Controlled Stage III Clinical Study of Dendrobium Huoshanense Suppository in Locally Advanced Rectal Cancer Patients Treated by Neoadjuvant Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluates the role of Dendrobium Huoshanense Suppository for radiation proctitis in&#xD;
      locally advanced rectal cancer treated by capecitabine and irinotecan based neoadjuvant&#xD;
      chemoradiation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>≥Grade 2 proctitis</measure>
    <time_frame>During chemoradiotherapy</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>CRT with Dendrobium huoshanense Suppository</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendrobium huoshanense Suppository: 1.7g rectal administration per day for 5 weeks&#xD;
Concurrent Chemoradiotherapy:&#xD;
Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2 (UGT1A1*28 and *6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1*28 and *6 ：7/7+GG or 6/6+AA or 6/7+GA）.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRT with Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Placebo: 1.7g rectal administration per day for 5 weeks&#xD;
Concurrent Chemoradiotherapy:&#xD;
Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2 (UGT1A1*28 and *6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1*28 and *6 ：7/7+GG or 6/6+AA or 6/7+GA）.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dendrobium Huoshanense Suppository</intervention_name>
    <description>1.7g rectal administration per day for 5 weeks</description>
    <arm_group_label>CRT with Dendrobium huoshanense Suppository</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. pathological confirmed rectum adenocarcinoma&#xD;
&#xD;
          2. clinical stage T3-4 and/or N+&#xD;
&#xD;
          3. the distance from anal verge less than 10 cm&#xD;
&#xD;
          4. without distance metastases&#xD;
&#xD;
          5. performance status score: 0~1&#xD;
&#xD;
          6. without previous anti-cancer therapy&#xD;
&#xD;
          7. able to follow the protocol during the study period&#xD;
&#xD;
          8. sign the inform consen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding women&#xD;
&#xD;
          2. Those with other history of malignant disease in the past 5 years, except for cured&#xD;
             skin cancer and cervical carcinoma in situ&#xD;
&#xD;
          3. If there is an uncontrolled history of epilepsy, central nervous system disease or&#xD;
             mental disorder, the investigator may determine that the clinical severity may hinder&#xD;
             the signing of informed consent or affect the patient's oral medication compliance.&#xD;
&#xD;
          4. Clinically severe (ie, active) heart disease, such as symptomatic coronary heart&#xD;
             disease, New York Heart Association (NYHA) class II or more severe congestive heart&#xD;
             failure or severe arrhythmia requiring medication intervention (see appendix 12), or a&#xD;
             history of myocardial infarction in the last 12 months&#xD;
&#xD;
          5. Organ transplantation requires immunosuppressive therapy Severe uncontrolled recurrent&#xD;
             infections, or other serious uncontrolled concomitant diseases&#xD;
&#xD;
          6. Subject blood routine and biochemical indicators do not meet the following criteria:&#xD;
             hemoglobin ≥ 90g / L; absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; Alanine&#xD;
             transaminase (ALT), aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of&#xD;
             normal; alkaline phosphatase (ALP) ≤2.5 times the normal upper limit; serum total&#xD;
             bilirubin &lt;1.5 times the normal upper limit; serum creatinine &lt;1 times the normal&#xD;
             upper limit; serum albumin ≥ 30g / L&#xD;
&#xD;
          7. Anyone who is allergic to any research medication&#xD;
&#xD;
          8. DPD deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ji Zhu, MD</last_name>
    <phone>571-88128142</phone>
    <phone_ext>+86</phone_ext>
    <email>leo.zhu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ji Zhu</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JI Zhu, MD</last_name>
      <phone>571-88128142</phone>
      <phone_ext>+86</phone_ext>
      <email>leo.zhu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>zhuji</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant Chemoradiotherapy</keyword>
  <keyword>Dendrobium Huoshanense</keyword>
  <keyword>irinotecan</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

